Article Text

Download PDFPDF
Review: quetiapine monotherapy improves response and remission compared with placebo in generalised anxiety disorder

Statistics from


  • Sources of funding The first author was funded by a Canadian Institutes of Health Research Fellowship.


  • Competing interests CUC has been a consultant and/or advisor to or has received honoraria from: Actelion, Alexza; AstraZeneca, Biotis, Bristol-Myers Squibb, Cephalon, Eli Lilly, GSK, IntraCellular Therapies; Ortho-McNeill/Janssen/J&J, Medavante, Merck, Novartis, Otsuka, Pfizer and Sunovion. He has received grant support from the Feinstein Institute for Medical Research, the National Institute of Mental Health (NIMH) and the National Alliance for Research in Schizophrenia and Depression (NARSAD), BMS, Otsuka and Ortho-McNeill/Janssen/J&J. MC has no conflicting interests.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.